Literature DB >> 26210507

Combating highly resistant emerging pathogen Mycobacterium abscessus and Mycobacterium tuberculosis with novel salicylanilide esters and carbamates.

Zsuzsa Baranyai1, Martin Krátký2, Jarmila Vinšová3, Nóra Szabó4, Zsuzsanna Senoner5, Kata Horváti6, Jiřina Stolaříková7, Sándor Dávid8, Szilvia Bősze9.   

Abstract

In the Mycobacterium genus over one hundred species are already described and new ones are periodically reported. Species that form colonies in a week are classified as rapid growers, those requiring longer periods (up to three months) are the mostly pathogenic slow growers. More recently, new emerging species have been identified to lengthen the list, all rapid growers. Of these, Mycobacterium abscessus is also an intracellular pathogen and it is the most chemotherapy-resistant rapid-growing mycobacterium. In addition, the cases of multidrug-resistant Mycobacterium tuberculosis infection are also increasing. Therefore there is an urgent need to find new active molecules against these threatening strains. Based on previous results, a series of salicylanilides, salicylanilide 5-chloropyrazinoates and carbamates was designed, synthesized and characterised. The compounds were evaluated for their in vitro activity on M. abscessus, susceptible M. tuberculosis H37Rv, multidrug-resistant (MDR) M. tuberculosis MDR A8, M. tuberculosis MDR 9449/2006 and on the extremely-resistant Praha 131 (XDR) strains. All derivatives exhibited a significant activity with minimum inhibitory concentrations (MICs) in the low micromolar range. Eight salicylanilide carbamates and two salicylanilide esters exhibited an excellent in vitro activity on M. abscessus with MICs from 0.2 to 2.1 μM, thus being more effective than ciprofloxacin and gentamicin. This finding is potentially promising, particularly, as M. abscessus is a threateningly chemotherapy-resistant species. M. tuberculosis H37Rv was inhibited with MICs from 0.2 μM, and eleven compounds have lower MICs than isoniazid. Salicylanilide esters and carbamates were found that they were effective also on MDR and XDR M. tuberculosis strains with MICs ≥1.0 μM. The in vitro cytotoxicity (IC50) was also determined on human MonoMac-6 cells, and selectivity index (SI) of the compounds was established. In general, salicylanilide derivatives substituted by halogens on both salicyl and aniline rings showed better activity, than 4-benzoylaniline derivatives. The ester or carbamate bond formation of parent salicylanilides mostly retained or improved antimycobacterial potency with moderate selectivity.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Antimycobacterial activity; Multidrug-resistant Mycobacterium tuberculosis; Mycobacterium abscessus; Salicylanilide; Salicylanilide 5-chloropyrazinoate; Salicylanilide carbamate

Mesh:

Substances:

Year:  2015        PMID: 26210507     DOI: 10.1016/j.ejmech.2015.07.001

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  10 in total

1.  Mycobacterium abscessus drug discovery using machine learning.

Authors:  Alan A Schmalstig; Kimberley M Zorn; Sebastian Murcia; Andrew Robinson; Svetlana Savina; Elena Komarova; Vadim Makarov; Miriam Braunstein; Sean Ekins
Journal:  Tuberculosis (Edinb)       Date:  2022-01-20       Impact factor: 3.131

2.  Synthesis and biological evaluation of novel 5-chloro-N-(4-sulfamoylbenzyl) salicylamide derivatives as tubulin polymerization inhibitors.

Authors:  Alaaeldin M F Galal; Maha M Soltan; Esam R Ahmed; Atef G Hanna
Journal:  Medchemcomm       Date:  2018-07-26       Impact factor: 3.597

Review 3.  NTM drug discovery: status, gaps and the way forward.

Authors:  Mu-Lu Wu; Dinah B Aziz; Véronique Dartois; Thomas Dick
Journal:  Drug Discov Today       Date:  2018-04-07       Impact factor: 7.851

4.  Small molecule QF84139 ameliorates cardiac hypertrophy via activating the AMPK signaling pathway.

Authors:  Xu-Xia Li; Peng Zhang; Yang Yang; Jing-Jing Wang; Yan-Jun Zheng; Ji-Liang Tan; Shen-Yan Liu; Yong-Ming Yan; You-Yi Zhang; Yong-Xian Cheng; Huang-Tian Yang
Journal:  Acta Pharmacol Sin       Date:  2021-05-09       Impact factor: 6.150

Review 5.  Pipeline of anti-Mycobacterium abscessus small molecules: Repurposable drugs and promising novel chemical entities.

Authors:  Anna Egorova; Mary Jackson; Victor Gavrilyuk; Vadim Makarov
Journal:  Med Res Rev       Date:  2021-03-01       Impact factor: 12.388

6.  Reporter-Based Assays for High-Throughput Drug Screening against Mycobacterium abscessus.

Authors:  Rashmi Gupta; Mandy Netherton; Thomas F Byrd; Kyle H Rohde
Journal:  Front Microbiol       Date:  2017-11-10       Impact factor: 5.640

7.  Design, Synthesis and Evaluation of N-pyrazinylbenzamides as Potential Antimycobacterial Agents.

Authors:  Jan Zitko; Alžběta Mindlová; Ondřej Valášek; Ondřej Jand'ourek; Pavla Paterová; Jiří Janoušek; Klára Konečná; Martin Doležal
Journal:  Molecules       Date:  2018-09-18       Impact factor: 4.411

8.  BINDER: computationally inferring a gene regulatory network for Mycobacterium abscessus.

Authors:  Patrick M Staunton; Aleksandra A Miranda-CasoLuengo; Brendan J Loftus; Isobel Claire Gormley
Journal:  BMC Bioinformatics       Date:  2019-09-10       Impact factor: 3.169

Review 9.  Looking beyond Typical Treatments for Atypical Mycobacteria.

Authors:  Clara M Bento; Maria Salomé Gomes; Tânia Silva
Journal:  Antibiotics (Basel)       Date:  2020-01-03

Review 10.  Multitargeting Compounds: A Promising Strategy to Overcome Multi-Drug Resistant Tuberculosis.

Authors:  Giovanni Stelitano; José Camilla Sammartino; Laurent Roberto Chiarelli
Journal:  Molecules       Date:  2020-03-09       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.